site map | search | contact | disclaimer     August 07, 2008   QLT INC. OUR BUSINESS IS SCIENCE. OUR PRODUCT IS LIFE. QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel® and punctal plugs with drugs, to create products such as Visudyne® and Eligard® and future product opportunities. CURRENT CLINICAL TRIALS All Trials Employee Login QLT Announces Second Quarter Results for 2008 July 29, 2008 QLT Announces Second Quarter 2008 Visudyne® Sales July 17, 2008 QLT Completes Divestment of Aczone® to Allergan for USD$150 Million July 14, 2008 More press releases in our News Center... BMO Capital Markets 2008 Focus on Healthcare Conference QLT will be presenting at 1:15 p.m. ET on Tuesday, August 5 in New York City. Click here to listen to the presentation. Q2 2008 Earnings Conference Call QLT broadcast its Q2 2008 Earnings Conference Call on Tuesday, July 29. Click here to listen to a replay of the webcast. Annual Meeting of Shareholders On Wednesday, May 14, QLT held its Annual Meeting of Shareholders in Vancouver, British Columbia. To listen to a replay of the webcast click here. Copyright © 2000 - 2008 QLT Inc. All rights reserved. See legal terms for use of site and Privacy Policy.